Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2017, Article ID 4385161, 7 pages
https://doi.org/10.1155/2017/4385161
Clinical Study

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial

1Department of Gastroenterology, Nagano Red Cross Hospital, Nagano, Japan
2Department of Metabolic Regulation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
3Digestive Disease Center, Showa Inan General Hospital, Komagane, Japan
4Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan

Correspondence should be addressed to Masafumi Maruyama; pj.ro.crj.dem-onagan@amayuram.m

Received 27 October 2016; Accepted 18 January 2017; Published 28 February 2017

Academic Editor: Michael Beyak

Copyright © 2017 Masafumi Maruyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [15 citations]

The following is the list of published articles that have cited the current article.

  • Anthony O'Connor, Dominique Lamarque, Javier P. Gisbert, and Colm O'Morain, “ Treatment of Helicobacter pylori infection 2017 ,” Helicobacter, vol. 22, pp. e12410, 2017. View at Publisher · View at Google Scholar
  • Shou Quan Dong, Tikka Prabhjot Singh, Xin Wei, Huang Yao, and Hong Ling Wang, “ A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? ,” Helicobacter, pp. e12438, 2017. View at Publisher · View at Google Scholar
  • Yan Chu, and Feng-Yuan Chen, “Helicobacter pylori eradication: Updated views and major controversies,” World Chinese Journal of Digestology, vol. 25, no. 27, pp. 2416–2426, 2017. View at Publisher · View at Google Scholar
  • Mika Miura, Masahiko Ohtaka, Mitsuhiko Hanawa, Naoki Shimura, Yoshioki Yoda, and Sho Suzuki, “Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for <i>Helicobacter pylori</i>,” Open Journal of Gastroenterology, vol. 07, no. 09, pp. 243–259, 2017. View at Publisher · View at Google Scholar
  • Neil R. O'Morain, Maria P. Dore, Anthony J. P. O'Connor, Javier P. Gisbert, and Colm A. O'Morain, “ Treatment of Helicobacter pylori infection in 2018 ,” Helicobacter, vol. 23, pp. e12519, 2018. View at Publisher · View at Google Scholar
  • Tadayuki Oshima, and Hiroto Miwa, “Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases,” Journal of Neurogastroenterology and Motility, vol. 24, no. 3, pp. 334–344, 2018. View at Publisher · View at Google Scholar
  • Hiroki Tanabe, Keiichi Yoshino, Katsuyoshi Ando, Yoshiki Nomura, Katsuhisa Ohta, Kiichi Satoh, Eiichiro Ichiishi, Akiei Ishizuka, Takaaki Otake, Yutaka Kohgo, Mikihiro Fujiya, and Toshikatsu Okumura, “Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication,” Annals of Clinical Microbiology and Antimicrobials, vol. 17, no. 1, 2018. View at Publisher · View at Google Scholar
  • Haruhiko Ozaki, Satoshi Harada, Toshihisa Takeuchi, Shinpei Kawaguchi, Yoshiaki Takahashi, Yuichi  Kojima, Kazuhiro Ota, Yasushi Hongo, Kiyoshi Ashida, Masahiro Sakaguchi, Satoshi Tokioka, Hiroki Sakamoto, Takahisa Furuta, Kazunari Tominaga, and Kazuhide Higuchi, “Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy,” Digestion, pp. 212–218, 2018. View at Publisher · View at Google Scholar
  • Jae Yong Park, and Jae Gyu Kim, “ New Helicobacter pylori Eradication Therapies ,” The Korean Journal of Gastroenterology, vol. 72, no. 5, pp. 237, 2018. View at Publisher · View at Google Scholar
  • Qiu-Ju Lyu, Qiang-Hong Pu, Xian-Fei Zhong, and Jin Zhang, “ Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials ,” BioMed Research International, vol. 2019, pp. 1–8, 2019. View at Publisher · View at Google Scholar
  • Amin Talebi Bezmin Abadi, and Enzo Ierardi, “Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?,” Frontiers in Pharmacology, vol. 10, 2019. View at Publisher · View at Google Scholar
  • Kazuma Fujimoto, Kojiro Kawachi, Hidenori Hidaka, Yasuhisa Sakata, Yoshimichi Takara, Megumi Hara, Hiroyoshi Endo, Ryo Nakano, Takuya Matsunaga, Nanae Tsuruoka, and Ryo Shimoda, “Smoking and drinking did not increase the failure of therapeutic helicobacter pylori eradication by vonoprazan, clarithromycin, and amoxicillin,” Digestion, vol. 99, no. 2, pp. 172–178, 2019. View at Publisher · View at Google Scholar
  • Naoki Chiba, “ Ulcer Disease and Helicobacter Pylori Infection: Current Treatment ,” Evidence-based Gastroenterology and Hepatology 4e, pp. 68–85, 2019. View at Publisher · View at Google Scholar
  • Sinéad M. Smith, Colm O’Morain, and Deirdre McNamara, “Helicobacter pylori resistance to current therapies,” Current Opinion in Gastroenterology, vol. 35, no. 1, pp. 6–13, 2019. View at Publisher · View at Google Scholar
  • Mitsushige Sugimoto, and Yoshio Yamaoka, “Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan,” Frontiers in Pharmacology, vol. 9, 2019. View at Publisher · View at Google Scholar